You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company plans to offer 3.75 million shares of its stock at $8 to $10 per share, and anticipates listing on the Nasdaq under ticker symbol "OPGN."
The gene editing company priced its initial public offering of 5.5 million American Depositary Shares with expectations of going public on the Nasdaq.
In an SEC document, the company said that current terms were not attractive enough for it to continue with a public offering.
The company was founded in 2002 with a whole-genome mapping technology and more recently moved into the microbial genetics space.
The firm said that it plans to list its stock on the Nasdaq under ticker symbol "RAIN" and added that its 2014 revenues were up 78 percent year over year to $30.6 million.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
The Australian company has also inked a deal to launch its proteomics-based kidney disease test in China.
The offering price and number of shares offered were above previous expectations, and Invitae's shares were up around 8 percent in Thursday morning trade.
The company said it plans to offer 3.75 million shares of its common stock and expects to fetch between $11 and $13 per share in its IPO.
The firm plans to offer 5,350,000 shares of its common stock at a price between $13 and $15 per share.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.